Integra LifeSciences (NASDAQ:IART) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $22.06 and traded as high as $26.28. Integra LifeSciences shares last traded at $25.22, with a volume of 773,625 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. Citigroup upped their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Finally, Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Price Performance

The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -280.19, a PEG ratio of 0.87 and a beta of 1.17. The stock’s 50-day moving average price is $23.81 and its 200 day moving average price is $22.06. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Insider Buying and Selling at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Integra LifeSciences

A number of institutional investors have recently bought and sold shares of the company. KBC Group NV increased its holdings in shares of Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after buying an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC acquired a new stake in Integra LifeSciences during the third quarter worth $73,000. Nisa Investment Advisors LLC raised its position in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Empowered Funds LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at $180,000. Finally, Centiva Capital LP purchased a new position in shares of Integra LifeSciences during the 3rd quarter worth $192,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.